HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cytochrome P450 epoxygenase metabolite, 14,15-EET, protects against isoproterenol-induced cellular hypertrophy in H9c2 rat cell line.

Abstract
We have previously shown that isoproterenol-induced cardiac hypertrophy causes significant changes to cytochromes P450 (CYPs) and soluble epoxide hydrolase (sEH) gene expression. Therefore, in this study, we examined the effect of isoproterenol in H9c2 cells, and the protective effects of 14,15-EET against isoproterenol-induced cellular hypertrophy. Isoproterenol was incubated with H9c2 cells for 24 and 48 h. To determine the protective effects of 14,15-EET, H9c2 cells were incubated with isoproterenol in the absence and presence of 14,15-EET. Thereafter, the expression of hypertrophic markers and different CYP genes were determined by real time-PCR. Our results demonstrated that isoproterenol significantly increased the expression of hypertrophic marker, atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), parallel to a significant increase in cell surface area. Also, isoproterenol increased the mRNA expression of CYP1A1, CYP1B1, CYP2J3, CYP4F4 and CYP4F5, as well as the gene encoding sEH, EPHX2. On other hand, 14,15-EET significantly attenuated the isoproterenol-mediated induction of ANP, BNP, CYP1A1, CYP2J3, CYP4F4, CYP4F5 and EPHX2. Moreover 14,15-EET prevented the isoproterenol-mediated increase in cell surface area. Interestingly, 20-hydroxyeicosatetraenoic acid (20-HETE) treatment caused similar effects to that of isoproterenol treatment and induced cellular hypertrophy in H9c2 cells. In conclusion, isoproterenol induces cellular hypertrophy and modulates the expression of CYPs and EPHX2 in H9c2 cells. Furthermore, 14,15-EET exerts a protective effect against isoproterenol-induced cellular hypertrophy whereas, 20-HETE induced cellular hypertrophy in H9c2 cells.
AuthorsMandy M Y Tse, Mona E Aboutabl, Hassan N Althurwi, Osama H Elshenawy, Ghada Abdelhamid, Ayman O S El-Kadi
JournalVascular pharmacology (Vascul Pharmacol) 2013 May-Jun Vol. 58 Issue 5-6 Pg. 363-73 ISSN: 1879-3649 [Electronic] United States
PMID23466634 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2013 Elsevier Inc. All rights reserved.
Chemical References
  • Hydroxyeicosatetraenoic Acids
  • RNA, Messenger
  • 20-hydroxy-5,8,11,14-eicosatetraenoic acid
  • 14,15-epoxy-5,8,11-eicosatrienoic acid
  • Cytochrome P-450 Enzyme System
  • Epoxide Hydrolases
  • EPHX2 protein, rat
  • 8,11,14-Eicosatrienoic Acid
  • Isoproterenol
Topics
  • 8,11,14-Eicosatrienoic Acid (analogs & derivatives, pharmacology)
  • Animals
  • Cardiomegaly (chemically induced, prevention & control)
  • Cell Line
  • Cytochrome P-450 Enzyme System (genetics)
  • Epoxide Hydrolases (genetics)
  • Gene Expression Regulation (drug effects)
  • Hydroxyeicosatetraenoic Acids (toxicity)
  • Isoproterenol (toxicity)
  • Myocytes, Cardiac (drug effects, pathology)
  • RNA, Messenger (metabolism)
  • Rats
  • Real-Time Polymerase Chain Reaction
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: